B
BCD Bioscience
Creates ingredients for food, ag, and bio-pharmaceutical applications
About BCD Bioscience
BCD Bio, operating under the brand name one.bio, is a health-focused startup that aims to revolutionize the food industry by reintroducing active fibers into our diets. The company operates in the health and wellness market, specifically targeting consumers who are conscious about their health and diet.
Read full description
The company's primary product, WholeFibers™, is a proprietary blend of natural plant fibers that are integrated back into food. The company's unique selling point is its ability to add these fibers into food invisibly and flavorlessly, without the need for messy powders, mixes, or expensive pills. This makes the product convenient and easy to incorporate into any diet.
BCD Bio's business model is centered around the production and sale of WholeFibers™. The company makes money by selling this product to consumers who are looking to improve their health and longevity by incorporating more active fibers into their diet.
The company's mission is to combat modern diseases associated with poor diet by making it easier for consumers to access the beneficial parts of food that are often missing from our modern diets. By doing so, one.bio aims to help consumers live longer and better lives.
BCD Bio's approach to health and wellness is rooted in a return to nature, using natural plant fibers to create a product that is both beneficial for health and easy to incorporate into a modern diet.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Davis, United States
- Employees
- 39
- Open positions
- None listed
- Dealroom signal
- 72.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Innovative Food
- Sector
- Biotech & Life Sciences, Biotechnology, Probiotics, Spinout, Alternative Protein, Sustainable Development Goals, Biotech and Pharma, Enabler of Alternative Proteins, Climate Tech, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning BCD Bioscience.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2022 | $12M | $48M | Seventure Partners · Collaborative Fund · Acre Venture Partners · Skyviews Life Science | ↗ |
| ANGEL✓Equity / VC | Jun 2020 | $4.5M | $18M | Undisclosed | — |
Growth signals
Latest recorded traffic for BCD Bioscience is 70 monthly website visits, down 85.1% over the last three months. BCD Bioscience's team declined 9.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Bill & Melinda Gates Foundation
Series A5 investors entered at this stage
Seventure Partners
Collaborative Fund
Acre Venture Partners
Skyviews Life Science
iSelect Fund
Other known investors4 additional known investors
Universiry of California, Davis
Argonautic Ventures
Ian Brady
SymBiosis
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BCD Bioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BCD Bioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.